Augmented antibacterial activity of ampicillin with silver nanoparticles against methicillin-resistant Staphylococcus aureus (MRSA).
At present, including failed attempts, it takes about 15 years and costs totaling up to $2.6 billion to take a promising new compound from laboratory to the market. Increasing drug resistance among microbial pathogens has led to a growing interest in exploring novel methods to enhance the efficacy of existing drugs. Combination therapies involving two or more known antimicrobial methods, particularly those involving nanoparticles for combating the clinical problems associated with antibiotic resistance, have been garnering interest. In the current study, we determined whether a combination therapy involving silver nanoparticles, which are known for their antimicrobial activity, and the widely used antibiotic ampicillin can be effective against methicillin-resistant Staphylococcus aureus (MRSA). In the presence of sub-lethal dose of silver nanoparticles, ampicillin was found to be effective against MRSA. Indeed, the results show that silver nanoparticles and ampicillin act synergistically, with the effect being more pronounced when a lower concentration of ampicillin is present. When present at a higher concentration, ampicillin coats the silver nanoparticle, preventing the direct interaction of nanoparticles and bacteria. This study discusses the possible applications of combination antimicrobial therapies involving silver nanoparticles for therapeutic treatments.